Log in

NYSEARCA:XPHSPDR S&P Pharmaceuticals ETF Stock Price, Forecast & News

$43.17
-0.01 (-0.02 %)
(As of 05/22/2020 04:00 PM ET)
Add
Today's Range
$42.94
Now: $43.17
$43.20
50-Day Range
$34.56
MA: $40.07
$43.60
52-Week Range
$30.30
Now: $43.17
$48.12
Volume58,136 shs
Average Volume122,337 shs
Market Capitalization$252.54 million
P/E RatioN/A
Dividend Yield0.68%
BetaN/A
SPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Fund invests substantially all, but at least 80%, of its total assets in the securities comprising the Index. In addition, the Fund may invest in equity securities that are not included in the Index, cash and cash equivalents or money market instruments, such as repurchase agreements and money market funds. The Pharmaceuticals Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.89 out of 5 stars


Basic Details

Issuer SSgA
Fund NameSPDR S&P Pharmaceuticals ETF
Tax ClassificationRegulated Investment Company
SymbolNYSEARCA:XPH
Inception Date6/19/2006
Fund ManagerMichael Feehily, Karl Schneider, Keith Richardson
Phone+1-617-6644738

Fund Focus

Asset ClassEquity
BenchmarkS&P Pharmaceuticals Index
CategorySector
FocusHealth Care
Development LevelDeveloped Markets
RegionNorth America

Fund Statistics

Assets Under Management$248.39 million
Average Daily Volume$110,297.80
Discount/Premium0.04%

ETF Expenses

Management Fee0.35%
Other Expenses0.00%
Total Expenses0.35%
Fee Waiver0.00%
Net Expenses0.35%

Administrator, Advisor and Custodian

AdministratorSSGA Funds Management, Inc.
AdvisorSSgA Funds Management, Inc.
CustodianState Street Bank and Trust Company
DistributorState Street Global Advisors Funds Distributors, LLC
Transfer AgentState Street Bank and Trust Company
Trustee
Lead Market MakerCredit Suisse

Receive XPH News and Ratings via Email

Sign-up to receive the latest news and ratings for XPH and its competitors with MarketBeat's FREE daily newsletter.

Geographic Exposure of SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH)
Currency Exposure of SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH)
Sector Exposure of SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH)
Industry Exposure of SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH)

SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) Frequently Asked Questions

How has SPDR S&P Pharmaceuticals ETF's stock been impacted by COVID-19 (Coronavirus)?

SPDR S&P Pharmaceuticals ETF's stock was trading at $37.41 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, XPH stock has increased by 15.4% and is now trading at $43.17. View which stocks have been most impacted by Coronavirus.

How often does SPDR S&P Pharmaceuticals ETF pay dividends? What is the dividend yield for SPDR S&P Pharmaceuticals ETF?

SPDR S&P Pharmaceuticals ETF announced a quarterly dividend on Monday, December 23rd. Stockholders of record on Tuesday, December 24th will be given a dividend of $0.0711 per share on Friday, December 27th. This represents a $0.28 annualized dividend and a yield of 0.66%. The ex-dividend date of this dividend is Monday, December 23rd. This is a positive change from SPDR S&P Pharmaceuticals ETF's previous quarterly dividend of $0.07. View SPDR S&P Pharmaceuticals ETF's dividend history.

Has SPDR S&P Pharmaceuticals ETF been receiving favorable news coverage?

News stories about XPH stock have been trending extremely negative this week, according to InfoTrie. The research firm scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. SPDR S&P Pharmaceuticals ETF earned a news impact score of -4.6 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. View the latest news aboutSPDR S&P Pharmaceuticals ETF.

What other stocks do shareholders of SPDR S&P Pharmaceuticals ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SPDR S&P Pharmaceuticals ETF investors own include Pfizer (PFE), Bank of America (BAC), Target (TGT), Broadcom (AVGO), ConocoPhillips (COP), Chevron (CVX), Docusign (DOCU), SPDR Gold Shares (GLD), JPMorgan Chase & Co. (JPM) and Micron Technology (MU).

Who are SPDR S&P Pharmaceuticals ETF's key executives?

SPDR S&P Pharmaceuticals ETF's management team includes the following people:
  • James E. Ross, President, Trustee (Age 52)
  • Peter A. Ambrosini, Chief Compliance Officer (Age 69)
  • Michael P. Riley, Vice President (Age 44)
  • Gary L. French, Treasurer (Age 64)
  • John W. Clark, Assistant Treasurer (Age 46)
  • Matthew W. Flaherty, Assistant Treasurer (Age 42)
  • Chad C. Hallett, Assistant Treasurer of Street tracks series trust (Age 47)
  • Mary Moran Zeven, Secretary (Age 52)
  • Scott M. Zoltowski, Assistant Secretary (Age 44)
  • Dave Kelly, Independent Trustee

What is SPDR S&P Pharmaceuticals ETF's stock symbol?

SPDR S&P Pharmaceuticals ETF trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "XPH."

Who are SPDR S&P Pharmaceuticals ETF's major shareholders?

SPDR S&P Pharmaceuticals ETF's stock is owned by a variety of retail and institutional investors. Top institutional investors include Morgan Stanley (14.52%), JPMorgan Chase & Co. (11.07%), Wharton Business Group LLC (2.47%), Financial Management Professionals Inc. (1.47%), Brookstone Capital Management (1.34%) and Hochman Cole Investment Advisors Inc. (1.11%).

Which major investors are selling SPDR S&P Pharmaceuticals ETF stock?

XPH stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Wharton Business Group LLC, UBS Group AG, Citigroup Inc., Hochman Cole Investment Advisors Inc., PNC Financial Services Group Inc., Nwam LLC, and Vista Investment Management.

Which major investors are buying SPDR S&P Pharmaceuticals ETF stock?

XPH stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Morgan Stanley, Financial Management Professionals Inc., Brookstone Capital Management, Cetera Investment Advisers, Nicolet Advisory Services LLC, IHT Wealth Management LLC, and AE Wealth Management LLC.

How do I buy shares of SPDR S&P Pharmaceuticals ETF?

Shares of XPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is SPDR S&P Pharmaceuticals ETF's stock price today?

One share of XPH stock can currently be purchased for approximately $43.17.

How big of a company is SPDR S&P Pharmaceuticals ETF?

SPDR S&P Pharmaceuticals ETF has a market capitalization of $252.54 million.

What is SPDR S&P Pharmaceuticals ETF's official website?

The official website for SPDR S&P Pharmaceuticals ETF is www.spdrs.com.

How can I contact SPDR S&P Pharmaceuticals ETF?

SPDR S&P Pharmaceuticals ETF's mailing address is State Street Financial Center One Lincoln Street, BOSTON, MA 02111, United States. The company can be reached via phone at +1-617-6644738.

This page was last updated on 5/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.